Psoriasis News Storm Increasing Arthritis No Competition Avoiding Triggers and Cosentyx .pdf
Original filename: Psoriasis News Storm - Increasing Arthritis No Competition Avoiding Triggers and Cosentyx.pdf
Title: Psoriasis News Storm – Increasing Arthritis, No Competition, Avoiding Triggers and Cosentyx
This PDF 1.4 document has been generated by wkhtmltopdf 0.12.2.1 / Qt 4.8.6, and has been sent on pdf-archive.com on 17/06/2018 at 00:25, from IP address 76.27.x.x.
The current document download page has been viewed 276 times.
File size: 331 KB (4 pages).
Privacy: public file
Download original PDF file
Psoriasis News Storm – Increasing Arthritis, No
Competition, Avoiding Triggers and Cosentyx
May 16, 2018
Cosentyx Gains FDA Approval for Scalp Psoriasis
For those suffering from moderate to severe scalp psoriasis, there is a potential light at the end
of the tunnel. The FDA recently approved Cosentyx to treat scalp psoriasis.
If you’re one of these people, I’d get in touch with my doctor and see if you’re a good candidate
for this new drug.
The FDA has approved a label update
for secukinumab (Cosentyx) for the
treatment of moderate-to-severe scalp
psoriasis, according to a Novartis press
release. Scalp psoriasis affects
approximately half of patients with
psoriasis and is notoriously difficult to
treat due to the presence of hair and
other related factors.
The label will be updated in the United
States immediately, according to the
thumbnail courtesy of specialtypharmacytimes.com
“Scalp psoriasis is on a very sensitive,
and a very visible area of the body. For patients this could translate into physical pain, frustration
and social isolation,” said Kristian Reich, MD, PhD, Georg-August-University Göttingen and
Dermatologikum Hamburg, Germany. “Patients and doctors are in need of effective treatment
options in this and other difficult-to-treat forms of psoriasis.”
Source: Cosentyx Gains FDA Approval for Scalp Psoriasis
Psoriatic Arthritis Rates Increasing in Taiwan Despite Leveling
This 13-year study in Taiwan aims to help identify psoriatic arthritis patients earlier. It’s really a
very interesting story if you can work your way through the scientific jargon.
One of the most interesting things to me was the increase in psoriatic arthritis with a decrease
in topical treatments.
Prevalence and incidence rates of psoriatic arthritis increased
significantly in Taiwan from 2000 to 2013, while psoriasis
exhibited no substantial change in incidence, according to
findings published in the Journal of Rheumatology .
The researchers also noted changes in medication patterns
during this period, with an increase in the use of biologics and
disease-modifying antirheumatic drugs and decreased use of
Source: Psoriatic arthritis rates increasing in Taiwan despite
U.S. Drug Companies Need Competition
Anyone who has spent any amount of money on prescriptions knows that they’re ridiculously
expensive. This letter to the editor shows how U.S. pharmaceutical companies are really
lagging behind other parts of the world when it comes to competition.
Unfortunately for people with autoimmune diseases like psoriasis, there’s almost no
competition in the biologics area.
Biologics are heavily advertised
and very expensive specialty
medications that have radically
changed the treatment course for
a range of conditions, from
cancer to autoimmune disorders.
Biologics can cost from $1,000
to $100,000 per month. Here in
the U.S., biologics account for
just 2 percent of prescription
drug utilization, but amount to
40 percent of prescription drug
spending, and the percentage is
The U.S. lags many parts of the world when it comes to bringing biosimilars to market. Just a few
biosimilars are available here. In Europe, where the first biosimilar was approved for use in 2006,
there now are 28 biosimilars available for a variety of conditions. They are safe, effective and
affordable alternatives to their high-priced biologic counterparts. According to the U.S. Food and
Drug Administration, patients can expect a biosimilar to produce a result that’s similar to the
result produced by its comparable biologic.
Remicade is a biologic produced by Johnson & Johnson to treat inflammatory conditions,
including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, plaque
psoriasis and ulcerative colitis. In the United States, the average annual cost of Remicade is
$28,000 per patient. Johnson & Johnson has raised the price of Remicade by 57 percent over the
past five years (many of those years had two price increases).
Source: Letter: U.S. drug companies need competition
Psoriasis Symptoms Limited by Avoiding These Trigger Foods
Angela Barber was able to contain her psoriasis flare-ups through diet. I know my flare-ups can
be postponed through a diet that avoids trigger foods. It doesn’t get rid of the flare-ups but it
does increase the time between them.
Angela Barber suffered from severe
psoriasis since she was 12 years old.
Her condition was so bad that she was
forced to take her own sheets when
travelling, to prevent further skin
Over the course of 50 years, Barber was
prescribed a range of “lotions and
potions”, including some very strong
drugs. But, nothing seemed to provide
thumbnail courtesy of express.co.uk
After a chance conversation with her dentist about food intolerances, she tried a DNA test to find
out whether she was intolerant to any types of foods.
Source: Psoriasis CURED by avoiding these trigger foods
For more psoriasis news, check out our psoriasis news page.
Be sure to read our reviews of the best shampoo for psoriasis and the best over the counter